<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5493064</article-id><article-id pub-id-type="publisher-id">525</article-id><article-id pub-id-type="doi">10.1186/s12944-017-0525-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cort&#x000e9;s</surname><given-names>V&#x000ed;ctor</given-names></name><address><email>vcortese@med.puc.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Quezada</surname><given-names>Nicol&#x000e1;s</given-names></name><address><email>nquezada@med.puc.cl</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uribe</surname><given-names>Sergio</given-names></name><address><email>suribe.uc@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Arrese</surname><given-names>Marco</given-names></name><address><email>marrese@med.puc.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nervi</surname><given-names>Flavio</given-names></name><address><email>fnervi@med.puc.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Departamento de Gastroenterolog&#x000ed;a, Facultad de Medicina, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>6513677 Santiago, Chile </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Departamento de Nutrici&#x000f3;n, Facultad de Medicina, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>6513677 Santiago, Chile </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Departamento de Cirug&#x000ed;a Digestiva, Facultad de Medicina, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>6513677 Santiago, Chile </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Divisi&#x000f3;n de Im&#x000e1;genes, Laboratorios y Patolog&#x000ed;as, Departamento de Radiolog&#x000ed;a y Centro de Im&#x000e1;genes Biom&#x000e9;dicas, Facultad de Medicina, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>6513677 Santiago, Chile </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Centro de Envejecimiento y Regeneraci&#x000f3;n (CARE), Departamento de Biolog&#x000ed;a Celular y Molecular, Facultad de Ciencias Biol&#x000f3;gicas, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>Santiago, Chile </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>129</elocation-id><history><date date-type="received"><day>19</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Nonalcoholic fatty liver disease (NAFLD) is highly prevalent worldwide. Experimental studies have shown that cholecystectomy (XGB) increases hepatic fat content in mice and appears associated to NAFLD in large retrospective population-based studies. The aim of this study was to prospectively assess the effects of XGB on hepatic fat content (HFC) and insulin resistance (IR) in non-obese, middle aged Hispanic subjects.</p></sec><sec><title>Methods</title><p id="Par2">Twenty-six gallstone patients undergoing elective XGB and 16 control subjects with normal livers and gallbladders at ultrasonography were prospectively followed 24&#x000a0;months for changes in HFC and IR. Clinical, biochemical determinations and hepatic imaging were performed at baseline and 24&#x000a0;months after surgery. MRI technique quantified HFC in four hepatic segments. IR was assessed by the Homeostasis Model Assessment (HOMA<sub>-IR</sub>) index.</p></sec><sec><title>Results</title><p id="Par3">Initial body mass index (BMI) was 25.6&#x000a0;&#x000b1;&#x000a0;0.4 and 24.3&#x000a0;&#x000b1;&#x000a0;1.0 in the control and XGB groups of subjects, respectively. Serum insulin level increased from 8.1&#x000a0;&#x000b1;&#x000a0;0.7 to 10.0&#x000a0;&#x000b1;&#x000a0;1.9 (&#x003bc;U/ml) 24&#x000a0;months after surgery in XGB patients (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05); no significant changes were detected in control individuals. Median HOMA<sub>-IR</sub> index increased from 1.31 (interquartile range, 1.01-1.68) to 2.20 (interquartile range, 1.57 - 2.60) 24&#x000a0;months after XGB, (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.003). Median HOMA<sub>-IR</sub> index of control subjects remained unchanged at the end of the study. Serum apoB concentration increased from 61.5&#x000a0;&#x000b1;&#x000a0;3.4 to 79.0&#x000a0;&#x000b1;&#x000a0;7.8 (&#x003bc;g/ml) in XGB patients (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.03). Serum apoB levels remained within normal ranges in both periods of the study in control subjects. HFC significantly increased in 2 of the 4 segments 24&#x000a0;months after XGB: right posterior hepatic lobe (from 5.3&#x000a0;&#x000b1;&#x000a0;0.2% to 6.0&#x000a0;&#x000b1;&#x000a0;0.2%, <italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.04) and right anterior hepatic lobe (from 5.8&#x000a0;&#x000b1;&#x000a0;0.2% to 6.6&#x000a0;&#x000b1;&#x000a0;0.3%, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.02). The average HFC of the four hepatic segments studied slightly increased from 5.4&#x000a0;&#x000b1;&#x000a0;0.2 to 5.8&#x000a0;&#x000b1;&#x000a0;0.3 2&#x000a0;years after XGB (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.03). No significant changes were found in HFC in the control subjects at the end of the study.</p></sec><sec><title>Conclusions</title><p id="Par100">Elective XGB increases HFC, HOMA<sub>-IR</sub> index and serum apoB concentration. These results support the notion that XGB is a risk factor non-alcoholic fatty liver disease and other IR &#x02013; associated disease conditions.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gallbladder</kwd><kwd>Cholecystectomy</kwd><kwd>Steatosis</kwd><kwd>NAFLD</kwd><kwd>Insulin resistance</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002850</institution-id><institution>Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico</institution></institution-wrap></funding-source><award-id>1130146</award-id><award-id>1150327</award-id><award-id>11150329</award-id><principal-award-recipient><name><surname>Arrese</surname><given-names>Marco</given-names></name><name><surname>Nervi</surname><given-names>Flavio</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Fondo Nacional Cient&#x000ed;fico y Tecnol&#x000f3;gico</institution></funding-source><award-id>1141134</award-id><principal-award-recipient><name><surname>Cort&#x000e9;s</surname><given-names>V&#x000ed;ctor</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>CONICYT</institution></funding-source><award-id>PIA/Basal PFB12/2007</award-id><principal-award-recipient><name><surname>Arrese</surname><given-names>Marco</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Conicyt Fondef/IDeA</institution></funding-source><award-id>ID15I10284</award-id><principal-award-recipient><name><surname>Uribe</surname><given-names>Sergio</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par28">Nonalcoholic fatty liver disease (NAFLD) is highly prevalent worldwide with an estimated rate of 30% among the adult population diagnosed by abdominal ultrasound [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. South American and Mexican American Hispanics have the highest prevalence rates of NAFLD with figures ranging between 30 to 50% of the population [<xref ref-type="bibr" rid="CR4">4</xref>]. NAFLD is frequently associated to obesity, type 2 diabetes, atherosclerosis and cholesterol gallstones [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>] with these entities sharing some metabolic alterations. NAFLD has a complex bidirectional pathogenic interrelationship with the metabolic syndrome (MS). NAFLD is considered both, a metabolic manifestation of MS and in some cases, a primary determinant of insulin resistance (IR) and the metabolic abnormalities clustered in the MS [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The natural history and possible evolution of NAFLD varies greatly in seriousness, starting as an accumulation of fat in the hepatocyte and potentially evolving towards nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par29">The cause of the increase of triglycerides (TG) in NAFLD has not been completely unveiled. However, it is known that IR is a fundamental pathogenic factor that alter each of the processes that regulate TG concentration in the liver by increasing hepatic lipogenesis and lipolysis from adipocytes, and decreasing peripheral lipoprotein lipase activity, producing an increase of chylomicron and VLDL remnants, which are rapidly cleared by the liver, thus resulting in a net TG accumulation in the organ [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par30">Cholecystectomy (XGB) is the recommended treatment for gallbladder (GB) diseases, including gallstone disease (GSD) and cholecystitis [<xref ref-type="bibr" rid="CR19">19</xref>]. Indeed, XGB is one of the most commonly performed surgical procedures worldwide [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and is considered a low-risk surgical procedure with no major long-term health implications. However, recent evidence shows that the GB may not only be a simple reservoir that stores, concentrates and delivers bile into the intestine for lipid absorption. Through its critical role in regulating bile acid (BA) metabolism and the recent finding that GB mucosa is rich in the hormone Fibroblast Growth Factor 19 (FGF19), this organ may have a physiological role in whole body metabolic homeostasis [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. In fact, the possibility that GB ablation may have metabolic consequences has emerged [<xref ref-type="bibr" rid="CR24">24</xref>] due to recent retrospective epidemiological studies showing that XGB may be a risk factor of NAFLD) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] and metabolic syndrome [<xref ref-type="bibr" rid="CR27">27</xref>]. Concordantly, experimental studies in mice have shown that XGB increases basal metabolic rate, serum and hepatic triglycerides concentration and very low-density lipoprotein (VLDL) production [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, XGB has been associated with elevated VLDL levels [<xref ref-type="bibr" rid="CR30">30</xref>], deteriorated postprandial glycemic control [<xref ref-type="bibr" rid="CR31">31</xref>] and weight gain [<xref ref-type="bibr" rid="CR32">32</xref>] in humans. The underlying mechanisms of these effects remain ill defined. Since BAs are important signaling molecules in controlling lipid and carbohydrate metabolism [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>] it is plausible that XGB may influence whole-body metabolic regulation through changes in BA physiology and potentially contributing to the development of IR and MS - associated conditions, particularly NAFLD [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par31">To better define the potential role of XGB as a risk factor of NAFLD, the present study aimed to prospectively evaluate the effects of XGB on liver fat content and IR, one of the most relevant factors underlying NAFLD development [<xref ref-type="bibr" rid="CR36">36</xref>]. To that end, we determined IR by the homeostatic model assessment index (HOMA-<sub>IR</sub>) [<xref ref-type="bibr" rid="CR37">37</xref>] and hepatic fat by magnetic resonance imaging (MRI) [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] in a series of non-obese GSD patients over a period of 24&#x000a0;months after elective XGB.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patient selection</title><p id="Par32">This study agreed with the ethical guidelines of Declaration of Helsinki (1975) and was approved by the Institutional Review Board for Human Studies of the Faculty of Medicine at <italic>Pontificia Universidad Cat&#x000f3;lica de Chile</italic>. All participants gave informed written consent prior to participate in this survey.</p><p id="Par33">We arbitrarily included 30 patients harboring asymptomatic gallstone disease subjected to elective laparoscopic XGB at the Clinical Hospital of the <italic>Pontificia Universidad Cat&#x000f3;lica de Chile</italic>, between January and August 2013. We also studied a group of 20 control subjects with similar clinical and biochemical characteristics and normal GBs at abdominal ultrasound. Twenty-six cholecystectomized patients and 16 control subjects completed the study 24&#x000a0;months later.</p><p id="Par34">All subjects were 35 to 55&#x000a0;years old, non-diabetic and non-obese who agreed to participate in the study. Inclusion criteria were: a) body mass index (BMI)&#x000a0;&#x0003c;&#x000a0;28 and no change in weight of more than 3&#x000a0;kg in the last 6&#x000a0;months before entering the study; b) fasting glucose, lipid levels and liver function tests within normal values; c) absence of hepatic steatosis assessed by abdominal ultrasound; d) no use of glucose- and lipid-lowering drugs, estrogens or androgens. Exclusion criteria were: a) abnormal serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentrations; b) hepatic pathologies on MRI; c) alcohol consumption &#x0003e;20&#x000a0;g per day in the last 3&#x000a0;years; e) substance abuse; f) significant systemic diseases and g) inability to undergo MRI.</p></sec><sec id="Sec4"><title>Clinical and biochemical assessments</title><p id="Par35">Baseline clinical evaluation included medical history, physical exam, and height and weight measurements to calculate body mass index (BMI). Venous blood samples were obtained after 12&#x000a0;h of fasting. Glucose, lipids, insulin, apolipoprotein B (apoB), ALT and AST serum levels were measured at the central laboratory of <italic>Pontificia Universidad Cat&#x000f3;lica de Chile</italic> Health Network. We used the homeostasis model assessment index (HOMA<sub>-IR</sub>) to define IR at fasting [20, 24]. We defined IR for non-obese middle-aged subjects when HOMA<sub>-IR</sub> values were &#x02265;2.53 according to a population &#x02013;based Chilean study [<xref ref-type="bibr" rid="CR40">40</xref>].</p></sec><sec id="Sec5"><title>Magnetic resonance imaging protocol and imaging analysis</title><p id="Par36">A magnetic resonance imaging (MRI) scanner (1.5&#x000a0;T Philips Achieva MRI scanner, Best, The Netherlands) was used to quantitate hepatic fat content (HFC) A fat fraction map of the liver was generated based on IDEAL method [<xref ref-type="bibr" rid="CR41">41</xref>]. Briefly, echo times were set to TE&#x000a0;=&#x000a0;2.3/ 3.5/ 4.7&#x000a0;ms, corresponding to the optimal echo times in IDEAL algorithm for 1.5&#x000a0;T [<xref ref-type="bibr" rid="CR42">42</xref>]. TRs and flip angles were chosen experimentally using fat-water-emulsion phantoms [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par37">MRI data was processed with OSIRIX software (OsiriX Foundation, Geneva, Switzerland) to extract water and fat images. Afterwards, fat fraction map was extracted using image calculator tool of Image J software (NIH, Bethesda, MA, USA). In the fat fraction map, one region of interest (ROI) was set in four segments of the liver avoiding vascular structures. Four segment of the liver were analyzed: right posterior hepatic lobe (RPHL), anterior hepatic lobe (RAHL), left medium hepatic lobe (LMHL) and left lower hepatic lobe (LLHL). Mean FF was calculated for each ROI. Additionally, a mean value of the fat fraction of the liver was calculated by averaging the fat fraction values of the four ROI.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par38">Parametric data were presented as mean&#x000a0;&#x000b1;&#x000a0;SE of the mean and non-parametric data were expressed as medians with interquartile values. Student&#x02019;s <italic>t</italic> test was used to compare parametric data. Wilcoxon test was used for non-parametric variables and paired Chi-square tests were used to compare frequencies. Prism software (Version 6, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">http://www.graphpad.com</ext-link>/) was used for statistical analysis. Differences were considered significant with <italic>P</italic> values &#x0003c;0.05.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par39">Table <xref rid="Tab1" ref-type="table">1</xref> show that age and sex distribution was similar in XGB patients and control subjects. Importantly, BMI was in the upper limit of the normal range in both groups at the beginning and end of the study. Fasting serum glucose, insulin, lipids and apoB were also equivalent and within the normal range at the beginning of the study (Table <xref rid="Tab1" ref-type="table">1</xref>). Twenty-four months after XGB, serum apoB levels of control individuals remained within normal ranges at end of the study (68.1&#x000a0;&#x000b1;&#x000a0;3.4 vs 63.1&#x000a0;&#x000b1;&#x000a0;2.8 (&#x003bc;g/ml), respectively). Serum apoB concentration of cholecystectomized patients increased from 61.5&#x000a0;&#x000b1;&#x000a0;3.4 to 79.0&#x000a0;&#x000b1;&#x000a0;7.8 (&#x003bc;g/ml) in cholecystectomized patients (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.03).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Age, weight, Body Mass Index (BMI), and biochemical parameters of the control and cholecystectomized individuals, at the beginning and end of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th colspan="2">Control (<italic>N</italic>&#x000a0;=&#x000a0;16)</th><th colspan="2">Cholecystectomy (<italic>N</italic>&#x000a0;=&#x000a0;26)</th></tr><tr><th>Time (months)</th><th>0</th><th>24</th><th>0</th><th>24</th></tr></thead><tbody><tr><td>Age</td><td>38.2&#x000a0;&#x000b1;&#x000a0;2.6</td><td/><td>37.3&#x000a0;&#x000b1;&#x000a0;1.7</td><td/></tr><tr><td>Female/male</td><td>10F/6M</td><td/><td>18F/8M</td><td/></tr><tr><td>Body weight (kg)</td><td>71.5&#x000a0;&#x000b1;&#x000a0;3.0</td><td>72.0&#x000a0;&#x000b1;&#x000a0;3.2</td><td>67.4&#x000a0;&#x000b1;&#x000a0;1.8</td><td>71.5&#x000a0;&#x000b1;&#x000a0;2.3</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td>26.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td>24.3&#x000a0;&#x000b1;&#x000a0;1.0</td><td>24.4&#x000a0;&#x000b1;&#x000a0;1.1</td></tr><tr><td>ALT (U/L)</td><td>23.5&#x000a0;&#x000b1;&#x000a0;3.2</td><td>27.9&#x000a0;&#x000b1;&#x000a0;4.7</td><td>23.5&#x000a0;&#x000b1;&#x000a0;3.2</td><td>27.9&#x000a0;&#x000b1;&#x000a0;4.7</td></tr><tr><td>AST (U/L)</td><td>23.5&#x000a0;&#x000b1;&#x000a0;7.1</td><td>11.6&#x000a0;&#x000b1;&#x000a0;7.7</td><td>21.4&#x000a0;&#x000b1;&#x000a0;3.7</td><td>22.7&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td>Serum glucose (mg/dl)</td><td>85&#x000a0;&#x000b1;&#x000a0;1.5</td><td>84&#x000a0;&#x000b1;&#x000a0;1.6</td><td>79&#x000a0;&#x000b1;&#x000a0;1.6</td><td>81&#x000a0;&#x000b1;&#x000a0;1.5</td></tr><tr><td>Serum insulin (&#x003bc;U/ml)</td><td>8.5&#x000a0;&#x000b1;&#x000a0;1.7</td><td>9.4&#x000a0;&#x000b1;&#x000a0;1.3</td><td>8.1&#x000a0;&#x000b1;&#x000a0;0.7</td><td>10.0&#x000a0;&#x000b1;&#x000a0;1.9<sup>*</sup>
</td></tr><tr><td>Total cholesterol (mg/dl)</td><td>179&#x000a0;&#x000b1;&#x000a0;8</td><td>182&#x000a0;&#x000b1;&#x000a0;7</td><td>172&#x000a0;&#x000b1;&#x000a0;6</td><td>197&#x000a0;&#x000b1;&#x000a0;8</td></tr><tr><td>LDL cholesterol (mg/dl)</td><td>105&#x000a0;&#x000b1;&#x000a0;7</td><td>110&#x000a0;&#x000b1;&#x000a0;8</td><td>100&#x000a0;&#x000b1;&#x000a0;6</td><td>117&#x000a0;&#x000b1;&#x000a0;7</td></tr><tr><td>HDL cholesterol (mg/dl)</td><td>50&#x000a0;&#x000b1;&#x000a0;3</td><td>49&#x000a0;&#x000b1;&#x000a0;3</td><td>48&#x000a0;&#x000b1;&#x000a0;2</td><td>55&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td>Triglycerides (mg/dl)</td><td>118&#x000a0;&#x000b1;&#x000a0;12</td><td>117&#x000a0;&#x000b1;&#x000a0;11</td><td>121&#x000a0;&#x000b1;&#x000a0;10</td><td>127&#x000a0;&#x000b1;&#x000a0;12</td></tr><tr><td>Serum apoB (&#x003bc;g/ml)</td><td>68.1&#x000a0;&#x000b1;&#x000a0;3.4</td><td>63.1&#x000a0;&#x000b1;&#x000a0;2.8</td><td>61.5&#x000a0;&#x000b1;&#x000a0;3.4</td><td>79.0&#x000a0;&#x000b1;&#x000a0;7.0<sup>#</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<italic>Plus</italic> minus values are means &#x000b1; SE, <italic>BMI</italic> body mass index, <italic>AST</italic> aspartate aminotransferase, <italic>ALT</italic> alanine aminotransferase, <italic>LDL</italic> low density lipoprotein, <italic>HDL</italic> high density lipoprotein, <italic>apoB</italic> apoprotein B. <sup><bold>*</bold></sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, <sup>#</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.03</p></table-wrap-foot></table-wrap>
</p><sec id="Sec8"><title>XGB is associated with elevated serum insulin concentration and HOMA<sub>-IR</sub> index</title><p id="Par40">Serum insulin level increased from 8.1&#x000a0;&#x000b1;&#x000a0;0.7 to 10.0&#x000a0;&#x000b1;&#x000a0;1.9 (&#x003bc;U/ml) 24&#x000a0;month after surgery in XGB patients (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05), whereas no significant changes were detected in control individuals (Table <xref rid="Tab1" ref-type="table">1</xref>). As shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, median HOMA<sub>-IR</sub> index of control subjects remained unchanged, from 1.42 (interquartile range, 1.02 &#x02013; 1.86) to 1.74 (interquartile range, 1.11 - 2.39) during the observational period. Contrariwise, median HOMA<sub>-IR</sub> index increased from 1.31 (interquartile range, 1.01-1.68) to 2.20 (interquartile range, 1.57 - 2.60) 24&#x000a0;months after XGB, (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.003).We operationally defined IR when HOMA<sub>-IR</sub> was &#x02265;2.53 for middle-age, non-obese Chilean subjects [<xref ref-type="bibr" rid="CR24">24</xref>]. Upon this definition, 15% of individuals in both groups had IR at the beginning of the study. Twenty-four months later, 61% of the patients subjected to XGB had HOMA<sub>-IR</sub>&#x000a0;&#x02265;&#x000a0;2.53, compared with only 12% in the control group of individuals (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Considered together, these results suggest that XGB determines increased circulating insulin levels and favors IR in non-obese individuals.<fig id="Fig1"><label>Fig. 1</label><caption><p>Effect of XGB on HOMA<sub>-IR</sub> index. Values represent the median and the interquartile ranges. White columns represent results at the beginning of the study and columns with grey dots represent results obtained at the end of the study. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.02; <sup>&#x000b6;</sup>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p></caption><graphic xlink:href="12944_2017_525_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec9"><title>XGB is associated with higher hepatic fat</title><p id="Par41">At the beginning of the study, all individuals of both groups had hepatic fat (HFC) lower than 8% as assessed by MRI, indicating that they had no, or mild steatosis [21,22]. Twenty-five cholecystectomized patients and 15 control subjects had a second MRI after 24&#x000a0;months of follow&#x02013;up. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows that HFC of the four segments studied remained unchanged after 24&#x000a0;months of follow up in the control group. Contrariwise, patients subjected to XGB significantly increased HFC in the right posterior hepatic lobe (RPHL) (5.3&#x000a0;&#x000b1;&#x000a0;0.2% to 6.0&#x000a0;&#x000b1;&#x000a0;0.2%, <italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.04) and in the right anterior hepatic lobe (RAHL) (5.8&#x000a0;&#x000b1;&#x000a0;0.2% to 6.6&#x000a0;&#x000b1;&#x000a0;0.3%, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.02). The average value of HFC of the 4 hepatic segments, slightly increased 7%, from 5.4&#x000a0;&#x000b1;&#x000a0;0.2% to 5.8&#x000a0;&#x000b1;&#x000a0;0.20% (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) in cholecystectomized patients. No significant change was found in the control group.<fig id="Fig2"><label>Fig. 2</label><caption><p>Effect of XGB on hepatic fat content. Columns represent the mean&#x000a0;&#x000b1;&#x000a0;SE of the percentage of HFC observed at the beginning and after 24&#x000a0;months of follow-up in control (panel <bold>a</bold>) and cholecystectomized subjects (panel <bold>b</bold>). White and black columns represent the values obtained at the beginning and end of the study. Four liver segments were analyzed: right posterior hepatic lobe, RPHL; right anterior hepatic lobe, RAHL; left medium hepatic lobe, LMHL; left lower hepatic lobe, LLHL, and mean value of the four lobes. White columns represent values at the beginning of the study and columns with grey dots represent values obtained at the end of the study. * <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.03</p></caption><graphic xlink:href="12944_2017_525_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par42">This prospective pilot study shows that XGB is associated with a significant increase in HFC, serum apoB and insulin levels, as well as in HOMA<sub>-IR</sub> index, in a cohort of non-obese Hispanic subjects. These findings provide support to the contention that, whereas XGB cures GSD and eliminates the risk of GB cancer, it may have relevant negative metabolic consequences [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], contributing to the development, or worsening of IR and its consequences. Of note, IR is a major pathophysiological determinant of type 2 diabetes, atherosclerotic vascular diseases [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>] and various cancers associated with obesity [<xref ref-type="bibr" rid="CR47">47</xref>]. Moreover, NAFLD has become the most prevalent liver condition worldwide and has intrinsic links with IR &#x02013; MS and a number of associated disease conditions, including cardiovascular diseases [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par43">The mechanisms underlying the observed metabolic effects of XGB in the present study remain to be clarified. The GB could theoretically regulate whole body IR/sensitivity by direct mechanisms, through signaling factors secreted by its mucosa, or indirectly by regulating the flux mass of BAs through the enterohepatic and systemic circulation during the fast-feeding cycles. One of the GB-derived factor that play a role in this setting could be FGF19. This ileal hormone regulates BA synthesis and GB filling and is highly expressed in GB mucosa and secreted into bile [4]. FGF19 has direct systemic metabolic effects on lipid and carbohydrate metabolism [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Of note, serum FGF19 levels decrease after XGB [<xref ref-type="bibr" rid="CR50">50</xref>] and have been found decreased in patients with NAFLD [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Thus, it could be hypothesized that dysregulation of FGF 19 after XGB may in part mediate the metabolic consequences of XGB observed in this study.</p><p id="Par44">With regard to XGB-induced changes in BA physiology, it is generally accepted that XGB determines a decrease in the size of the BA pool [<xref ref-type="bibr" rid="CR22">22</xref>] and increases the enterohepatic recirculation rates of BA in the fasting state [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]; the BA pool recycles at least twice as often as normal after XGB [<xref ref-type="bibr" rid="CR55">55</xref>]. BA are recognized as relevant signaling molecules [<xref ref-type="bibr" rid="CR34">34</xref>] that may be critically involved in NAFLD development through their hepatic and extrahepatic effects regulating lipid and carbohydrate metabolic pathways, as well as energy homeostasis [<xref ref-type="bibr" rid="CR56">56</xref>]. On these grounds, XGB may theoretically determine elevated exposure of both cell surface and nuclear receptors to BAs, leading to pathological effects on triglycerides and glucose homeostasis [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par45">In our view, three major conclusions can be drawn from this study. The first relates to the observation that XGB favors lipid accumulation in the liver 24&#x000a0;months after surgery. We obtained these results using validated highly sensitive MRI methods [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] that allowed us to evaluate the statistical significance of small changes in the fat fraction of individual liver segments. In fact, although the actual magnitude of the increase in HFC after XGB was small, it is remarkable that these changes occurred in a relatively short time period and reached statistical significance. This result is consistent with the increased prevalence of NAFLD in patients that have underwent XGB reported in two large retrospective population-based studies in North American [<xref ref-type="bibr" rid="CR25">25</xref>] and Asian populations [<xref ref-type="bibr" rid="CR26">26</xref>]. Furthermore, a study based on the US National Health and Nutrition Examination Survey (NHANES) showed that XGB, but not GSD, was associated to cirrhosis and elevated serum liver enzymes [<xref ref-type="bibr" rid="CR57">57</xref>]. Secondly, in our best knowledge, this is the first prospective study showing that GB ablation associates with increased serum insulin levels and HOMA-<sub>IR</sub> index in humans. These findings are consistent with a number of retrospective cross-sectional epidemiological analyses showing that cholecystectomized patients have increased risks of MS [<xref ref-type="bibr" rid="CR27">27</xref>], arteriosclerotic vascular diseases [<xref ref-type="bibr" rid="CR58">58</xref>] and NAFLD [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Our third conclusion is that the observed increase in HFC and HOMA-<sub>IR</sub> index 24&#x000a0;months after XGB supports the hypothesis that NAFLD and IR could develop after XGD due to the recently discovered metabolic roles of GB [<xref ref-type="bibr" rid="CR22">22</xref>]. In a previous mouse study, we found that XGB increases serum and hepatic triglyceride concentrations along with higher VLDL and apoB production [<xref ref-type="bibr" rid="CR28">28</xref>]. Although not dynamic measurements of insulin sensitivity/resistance are available for those experiments, the metabolic changes observed are suggestive of hepatic IR [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In addition, the elevated levels of apoB, 24&#x000a0;months after XGB is also suggestive of systemic and hepatic IR, since insulin increases the secretion and decreases the clearance of apoB [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par46">Based on our current results and the commented experimental and epidemiological evidence, it is theoretically conceivable that a primary altered GB function, even in the absence of GSD, could induce not only gallstone formation, but also potentiate systemic negative metabolic changes. In fact, diabetic patients and individuals with IR with no evidence of gallstones, have abnormal GB motility [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>], possibly changing their BA kinetics and exposing enterohepatic and peripheral tissues to changes in BA metabolic effects.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par47">Our results are consistent with previous retrospective epidemiological surveys showing that XGB, but not GBD appears associated as a risk factor of metabolic syndrome-associated complications, particularly to NAFLD. Although this study was performed in a relatively small number of non-obese individuals, it is plausible that XGB could further increase the risk of IR and associated disease conditions in individuals with elevated basal metabolic risk, including obesity and diabetes. Our findings stress the necessity to prevent GSD and perform longer and larger prospective studies to more precisely disclose the metabolic consequences of GB ablation.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ALT</term><def><p id="Par4">Alanine aminotransferase</p></def></def-item><def-item><term>Apo B</term><def><p id="Par5">Apolipoprotein B</p></def></def-item><def-item><term>AST</term><def><p id="Par6">Aspartate aminotransferase</p></def></def-item><def-item><term>BA</term><def><p id="Par7">Bile acid</p></def></def-item><def-item><term>BMI</term><def><p id="Par8">Body mass index</p></def></def-item><def-item><term>FF</term><def><p id="Par9">Fat fraction</p></def></def-item><def-item><term>FGF19</term><def><p id="Par10">Fibroblast growth factor 19</p></def></def-item><def-item><term>GSD</term><def><p id="Par11">Gallstone disease</p></def></def-item><def-item><term>HDL</term><def><p id="Par12">High density lipoprotein</p></def></def-item><def-item><term>HFC</term><def><p id="Par13">Hepatic fat content</p></def></def-item><def-item><term>HOMA-IR</term><def><p id="Par14">Homeostasis model assessment index</p></def></def-item><def-item><term>IDEAL</term><def><p id="Par15">Iterative decomposition of water and fat with echo asymmetry and least squares estimation</p></def></def-item><def-item><term>LDL</term><def><p id="Par16">Low density lipoprotein</p></def></def-item><def-item><term>LLHL</term><def><p id="Par17">Left lower hepatic lobe</p></def></def-item><def-item><term>LMHL</term><def><p id="Par18">Left medium hepatic lobe</p></def></def-item><def-item><term>MRI</term><def><p id="Par19">Magnetic resonance imaging</p></def></def-item><def-item><term>ms</term><def><p id="Par20">Milliseconds</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par21">Non-alcoholic fatty liver disease</p></def></def-item><def-item><term>NASH</term><def><p id="Par22">Non-alcoholic steatohepatitis</p></def></def-item><def-item><term>RAHL</term><def><p id="Par23">Right anterior hepatic lobe</p></def></def-item><def-item><term>ROI</term><def><p id="Par24">Region of interest</p></def></def-item><def-item><term>RPHL</term><def><p id="Par25">Right posterior hepatic lobe</p></def></def-item><def-item><term>VLDL</term><def><p id="Par26">Very low-density lipoprotein</p></def></def-item><def-item><term>XGB</term><def><p id="Par27">Cholecystectomy</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Authors wish to thank Bogomila Batic and Ludwig Amigo for excellent technical assistance.</p><sec id="FPar1"><title>Availability of data and material</title><p id="Par48">The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar2"><title>Funding</title><p id="Par49">This study was supported by the following grants from the <italic>Fondo Nacional Cient&#x000ed;fico y Tecnol&#x000f3;gico</italic> (FONDECYT): 1130146 to FN, 11150329 to N.Q., 1141036 to S.U., 1141134 to VC and 1150327 to MA), and by a grant from the Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica (CONICYT) (PIA/Basal PFB12/2007, CARE Chile UC to M.A.), and Conicyt Fondef/IDeA, ID15I10284 to SU.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>VC, MA and FN designed the research, performed the statistical analysis; NQ recruited the patients and collected the data; SU performed NMR images and calculated hepatic fat&#x000a0;content; VC, NQ, SU, MA, FN analyzed the data; MA and FN wrote the paper. All authors approved this final version of the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par50">The study was reviewed and approved by the <italic>Pontificia Universidad Cat&#x000f3;lica de Chile</italic> Review Board. All study participants provided informed written consent prior to study enrollment.</p></sec><sec id="FPar4"><title>Consent for Publication</title><p id="Par51">In submitting this article to LIPIDS IN HEALTH AND DISEASE published by BioMed Central I certify that;</p><p id="Par52">1. I am authorized by my co-authors to enter into these arrangements.</p><p id="Par53">2. I warrant, on behalf of myself and my co-authors, that:</p><p id="Par54">&#x025cb; he article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;</p><p id="Par55">&#x025cb; I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to BioMed Central are not in breach of any other obligation; the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;</p><p id="Par56">I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.</p><p id="Par57">3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution License 4.0</ext-link>. In line with <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/about/policies/open-data">BioMed Central's Open Data Policy</ext-link>, data included in the article shall be made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons 1.0 Public Domain Dedication waiver</ext-link>, unless otherwise stated. If the law requires that the article be published in the public domain, I/we will notify BioMed Central at the time of submission, and in such cases not only the data but also the article shall be released under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons 1.0 Public Domain Dedication waiver</ext-link>. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution License 4.0</ext-link> or the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons 1.0 Public Domain Dedication waiver.</ext-link>
</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par58">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par59">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellentani</surname><given-names>S</given-names></name></person-group><article-title>The epidemiology of non-alcoholic fatty liver disease</article-title><source>Liver Int</source><year>2017</year><volume>37</volume><issue>Suppl 1</issue><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/liv.13299</pub-id><?supplied-pmid 28052624?><pub-id pub-id-type="pmid">28052624</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Koenig</surname><given-names>AB</given-names></name><name><surname>Abdelatif</surname><given-names>D</given-names></name><name><surname>Fazel</surname><given-names>Y</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Wymer</surname><given-names>M</given-names></name></person-group><article-title>Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes</article-title><source>Hepatology</source><year>2016</year><volume>64</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/hep.28431</pub-id><?supplied-pmid 26707365?><pub-id pub-id-type="pmid">26707365</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Harman</surname><given-names>DJ</given-names></name><name><surname>Card</surname><given-names>TR</given-names></name><name><surname>Aithal</surname><given-names>GP</given-names></name><name><surname>Guha</surname><given-names>IN</given-names></name></person-group><article-title>Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review</article-title><source>Lancet Gastroenterology Hepatology</source><year>2017</year><volume>2</volume><issue>4</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(16)30205-9</pub-id><?supplied-pmid 28404158?><pub-id pub-id-type="pmid">28404158</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saab</surname><given-names>S</given-names></name><name><surname>Manne</surname><given-names>V</given-names></name><name><surname>Nieto</surname><given-names>J</given-names></name><name><surname>Schwimmer</surname><given-names>JB</given-names></name><name><surname>Chalasani</surname><given-names>NP</given-names></name></person-group><article-title>Nonalcoholic Fatty Liver Disease in Latinos</article-title><source>Clin Gastroenterol Hepatol</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2015.05.001</pub-id><?supplied-pmid 25976180?><pub-id pub-id-type="pmid">25976180</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name></person-group><article-title>NAFLD: a multisystem disease</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><issue>1 Suppl</issue><fpage>S47</fpage><lpage>S64</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.12.012</pub-id><?supplied-pmid 25920090?><pub-id pub-id-type="pmid">25920090</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>P</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease, obesity and the metabolic syndrome</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2014</year><volume>28</volume><issue>4</issue><fpage>637</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2014.07.008</pub-id><?supplied-pmid 25194181?><pub-id pub-id-type="pmid">25194181</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>MH</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?</article-title><source>Scand J Gastroenterol</source><year>2014</year><volume>49</volume><issue>5</issue><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.3109/00365521.2014.894119</pub-id><?supplied-pmid 24646400?><pub-id pub-id-type="pmid">24646400</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name></person-group><article-title>Metabolic syndrome pandemic</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><issue>4</issue><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.151092</pub-id><?supplied-pmid 18174459?><pub-id pub-id-type="pmid">18174459</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yki-Jarvinen</surname><given-names>H</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>11</issue><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70032-4</pub-id><?supplied-pmid 24731669?><pub-id pub-id-type="pmid">24731669</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeda-Valdes</surname><given-names>P</given-names></name><name><surname>Aguilar-Olivos</surname><given-names>N</given-names></name><name><surname>Uribe</surname><given-names>M</given-names></name><name><surname>Mendez-Sanchez</surname><given-names>N</given-names></name></person-group><article-title>Common features of the metabolic syndrome and nonalcoholic fatty liver disease</article-title><source>Rev Recent Clin Trials</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>148</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.2174/1574887109666141216103908</pub-id><?supplied-pmid 25514910?><pub-id pub-id-type="pmid">25514910</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duseja</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Saraswat</surname><given-names>VA</given-names></name><name><surname>Acharya</surname><given-names>SK</given-names></name><name><surname>Chawla</surname><given-names>YK</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><etal/></person-group><article-title>Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology</article-title><source>J Clinical Experimental Hepatology</source><year>2015</year><volume>5</volume><issue>1</issue><fpage>51</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2015.02.006</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonardo</surname><given-names>A</given-names></name><name><surname>Ballestri</surname><given-names>S</given-names></name><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Angulo</surname><given-names>P</given-names></name><name><surname>Loria</surname><given-names>P</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome</article-title><source>Dig Liver Dis</source><year>2015</year><volume>47</volume><issue>3</issue><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2014.09.020</pub-id><?supplied-pmid 25739820?><pub-id pub-id-type="pmid">25739820</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrain</surname><given-names>S</given-names></name><name><surname>Rinella</surname><given-names>ME</given-names></name></person-group><article-title>A myriad of pathways to NASH</article-title><source>Clin. Liver Dis</source><year>2012</year><volume>16</volume><issue>3</issue><fpage>525</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2012.05.009</pub-id><?supplied-pmid 22824479?><pub-id pub-id-type="pmid">22824479</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>GB</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name></person-group><article-title>Natural History of Nonalcoholic Fatty Liver Disease</article-title><source>Dig Dis Sci</source><year>2016</year><volume>61</volume><issue>5</issue><fpage>1226</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1007/s10620-016-4095-4</pub-id><?supplied-pmid 27003142?><pub-id pub-id-type="pmid">27003142</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Italian Association for the Study of the L</collab></person-group><article-title>AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions</article-title><source>Dig Liver Dis</source><year>2017</year><volume>49</volume><issue>5</issue><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2017.01.147</pub-id><pub-id pub-id-type="pmid">28215516</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name></person-group><article-title>Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease</article-title><source>J Gastroenterol</source><year>2013</year><volume>48</volume><issue>4</issue><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1007/s00535-013-0758-5</pub-id><?supplied-pmid 23397118?><pub-id pub-id-type="pmid">23397118</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkenfeld</surname><given-names>AL</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><issue>2</issue><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1002/hep.26672</pub-id><?supplied-pmid 23929732?><pub-id pub-id-type="pmid">23929732</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Jelenik T, Kaul K, Sequaris G, Flogel U, Phielix E, Kotzka J, et al. Mechanisms of Insulin Resistance in Primary and Secondary Non-Alcoholic Fatty Liver. Diabetes. 2017; PubMed</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EASL</collab></person-group><article-title>Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones</article-title><source>J Hepatol</source><year>2016</year><volume>65</volume><issue>1</issue><fpage>146</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.03.005</pub-id><pub-id pub-id-type="pmid">27085810</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csikesz</surname><given-names>NG</given-names></name><name><surname>Singla</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Tseng</surname><given-names>JF</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name></person-group><article-title>Surgeon volume metrics in laparoscopic cholecystectomy</article-title><source>Dig Dis Sci</source><year>2010</year><volume>55</volume><issue>8</issue><fpage>2398</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1007/s10620-009-1035-6</pub-id><?supplied-pmid 19911275?><pub-id pub-id-type="pmid">19911275</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>MW</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Thiny</surname><given-names>MT</given-names></name><name><surname>Gangarosa</surname><given-names>LM</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Ringel</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Digestive and liver diseases statistics, 2004</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><issue>5</issue><fpage>1448</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.01.025</pub-id><?supplied-pmid 15131804?><pub-id pub-id-type="pmid">15131804</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Housset</surname><given-names>C</given-names></name><name><surname>Chretien</surname><given-names>Y</given-names></name><name><surname>Debray</surname><given-names>D</given-names></name><name><surname>Chignard</surname><given-names>N</given-names></name></person-group><article-title>Functions of the Gallbladder</article-title><source>Comprehensive Physiology.</source><year>2016</year><volume>6</volume><issue>3</issue><fpage>1549</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1002/cphy.c150050</pub-id><?supplied-pmid 27347902?><pub-id pub-id-type="pmid">27347902</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanlungo</surname><given-names>S</given-names></name><name><surname>Rigotti</surname><given-names>A</given-names></name><name><surname>Miquel</surname><given-names>JF</given-names></name><name><surname>Nervi</surname><given-names>F</given-names></name></person-group><article-title>Abnormalities of lipid metabolism, gallstone disease and gallbladder function</article-title><source>Clinical Lipidology</source><year>2011</year><volume>6</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.2217/clp.11.22</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nervi</surname><given-names>F</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name></person-group><article-title>Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences?</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><issue>6</issue><fpage>959</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/ajg.2013.84</pub-id><?supplied-pmid 23735917?><pub-id pub-id-type="pmid">23735917</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruhl</surname><given-names>CE</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name></person-group><article-title>Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><issue>6</issue><fpage>952</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1038/ajg.2013.70</pub-id><?supplied-pmid 23545713?><pub-id pub-id-type="pmid">23545713</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chung</surname><given-names>GE</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name></person-group><article-title>Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><issue>20</issue><fpage>6287</fpage><lpage>6295</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i20.6287</pub-id><?supplied-pmid 26034364?><pub-id pub-id-type="pmid">26034364</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Association of cholecystectomy with metabolic syndrome in a Chinese population</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>2</issue><fpage>e88189</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0088189</pub-id><?supplied-pmid 24505425?><pub-id pub-id-type="pmid">24505425</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amigo</surname><given-names>L</given-names></name><name><surname>Husche</surname><given-names>C</given-names></name><name><surname>Zanlungo</surname><given-names>S</given-names></name><name><surname>Lutjohann</surname><given-names>D</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name><name><surname>Miquel</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice</article-title><source>Liver Int</source><year>2011</year><volume>31</volume><issue>1</issue><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2010.02361.x</pub-id><?supplied-pmid 21040411?><pub-id pub-id-type="pmid">21040411</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>V</given-names></name><name><surname>Amigo</surname><given-names>L</given-names></name><name><surname>Zanlungo</surname><given-names>S</given-names></name><name><surname>Galgani</surname><given-names>J</given-names></name><name><surname>Robledo</surname><given-names>F</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metabolic effects of cholecystectomy: gallbladder ablation increases basal metabolic rate through G-protein coupled bile acid receptor Gpbar1-dependent mechanisms in mice</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>3</issue><fpage>e0118478</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0118478</pub-id><?supplied-pmid 25738495?><pub-id pub-id-type="pmid">25738495</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juvonen</surname><given-names>T</given-names></name><name><surname>Kervinen</surname><given-names>K</given-names></name><name><surname>Kairaluoma</surname><given-names>MI</given-names></name><name><surname>Kesaniemi</surname><given-names>YA</given-names></name></person-group><article-title>Effect of cholecystectomy on plasma lipid and lipoprotein levels</article-title><source>Hepato-Gastroenterology</source><year>1995</year><volume>42</volume><issue>4</issue><fpage>377</fpage><lpage>382</lpage><?supplied-pmid 8586372?><pub-id pub-id-type="pmid">8586372</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonne</surname><given-names>DP</given-names></name><name><surname>Hare</surname><given-names>KJ</given-names></name><name><surname>Martens</surname><given-names>P</given-names></name><name><surname>Rehfeld</surname><given-names>JF</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Vilsboll</surname><given-names>T</given-names></name><etal/></person-group><article-title>Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2013</year><volume>304</volume><issue>4</issue><fpage>G413</fpage><lpage>G419</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00435.2012</pub-id><?supplied-pmid 23275610?><pub-id pub-id-type="pmid">23275610</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>RB</given-names></name><name><surname>Cahill</surname><given-names>RA</given-names></name><name><surname>Watson</surname><given-names>RG</given-names></name></person-group><article-title>Weight gain after laparoscopic cholecystectomy</article-title><source>Ir J Med Sci</source><year>2004</year><volume>173</volume><issue>1</issue><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/BF02914515</pub-id><?supplied-pmid 15732228?><pub-id pub-id-type="pmid">15732228</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schonewille</surname><given-names>M</given-names></name><name><surname>de Boer</surname><given-names>JF</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name></person-group><article-title>Bile salts in control of lipid metabolism</article-title><source>Curr Opin Lipidol</source><year>2016</year><volume>27</volume><issue>3</issue><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1097/MOL.0000000000000303</pub-id><?supplied-pmid 27031274?><pub-id pub-id-type="pmid">27031274</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>JY</given-names></name></person-group><article-title>Bile acid metabolism and signaling</article-title><source>Comprehensive Physiology</source><year>2013</year><volume>3</volume><issue>3</issue><fpage>1191</fpage><lpage>1212</lpage><?supplied-pmid 23897684?><pub-id pub-id-type="pmid">23897684</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arab</surname><given-names>JP</given-names></name><name><surname>Karpen</surname><given-names>SJ</given-names></name><name><surname>Dawson</surname><given-names>PA</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name></person-group><article-title>Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><issue>1</issue><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1002/hep.28709</pub-id><?supplied-pmid 27358174?><pub-id pub-id-type="pmid">27358174</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gariani</surname><given-names>K</given-names></name><name><surname>Philippe</surname><given-names>J</given-names></name><name><surname>Jornayvaz</surname><given-names>FR</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside</article-title><source>Diabetes Metab</source><year>2013</year><volume>39</volume><issue>1</issue><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.diabet.2012.11.002</pub-id><?supplied-pmid 23266468?><pub-id pub-id-type="pmid">23266468</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><issue>7</issue><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><?supplied-pmid 3899825?><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idilman</surname><given-names>IS</given-names></name><name><surname>Aniktar</surname><given-names>H</given-names></name><name><surname>Idilman</surname><given-names>R</given-names></name><name><surname>Kabacam</surname><given-names>G</given-names></name><name><surname>Savas</surname><given-names>B</given-names></name><name><surname>Elhan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy</article-title><source>Radiology</source><year>2013</year><volume>267</volume><issue>3</issue><fpage>767</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1148/radiol.13121360</pub-id><?supplied-pmid 23382293?><pub-id pub-id-type="pmid">23382293</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Bydder</surname><given-names>M</given-names></name><name><surname>Wolfson</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis</article-title><source>Radiology</source><year>2013</year><volume>267</volume><issue>2</issue><fpage>422</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1148/radiol.12120896</pub-id><?supplied-pmid 23382291?><pub-id pub-id-type="pmid">23382291</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta</surname><given-names>AM</given-names></name><name><surname>Escalona</surname><given-names>M</given-names></name><name><surname>Maiz</surname><given-names>A</given-names></name><name><surname>Pollak</surname><given-names>F</given-names></name><name><surname>Leighton</surname><given-names>F</given-names></name></person-group><article-title>Determination of the insulin resistance index by the Homeostasis Model Assessment in a population of Metropolitan Region in Chile</article-title><source>Revista medica de Chile</source><year>2002</year><volume>130</volume><issue>11</issue><fpage>1227</fpage><lpage>1231</lpage><?supplied-pmid 12587504?><pub-id pub-id-type="pmid">12587504</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeder</surname><given-names>SB</given-names></name><name><surname>Pineda</surname><given-names>AR</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Shimakawa</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Brittain</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging</article-title><source>Magn Reson Med</source><year>2005</year><volume>54</volume><issue>3</issue><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1002/mrm.20624</pub-id><?supplied-pmid 16092103?><pub-id pub-id-type="pmid">16092103</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>GH</given-names></name></person-group><article-title>Multipoint Dixon technique for water and fat proton and susceptibility imaging</article-title><source>J Magn Reson Imaging</source><year>1991</year><volume>1</volume><issue>5</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1002/jmri.1880010504</pub-id><?supplied-pmid 1790376?><pub-id pub-id-type="pmid">1790376</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arboleda</surname><given-names>C</given-names></name><name><surname>Aguirre-Reyes</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>MP</given-names></name><name><surname>Tejos</surname><given-names>C</given-names></name><name><surname>Munoz</surname><given-names>L</given-names></name><name><surname>Miquel</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Total liver fat quantification using three-dimensional respiratory self-navigated MRI sequence</article-title><source>Magn Reson Med</source><year>2016</year><volume>76</volume><issue>5</issue><fpage>1400</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1002/mrm.26028</pub-id><?supplied-pmid 26588040?><pub-id pub-id-type="pmid">26588040</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotbolcu</surname><given-names>H</given-names></name><name><surname>Zorlu</surname><given-names>E</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease as a multi-systemic disease</article-title><source>World J Gastroenterol</source><year>2016</year><volume>22</volume><issue>16</issue><fpage>4079</fpage><lpage>4090</lpage><pub-id pub-id-type="doi">10.3748/wjg.v22.i16.4079</pub-id><?supplied-pmid 27122660?><pub-id pub-id-type="pmid">27122660</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>BW</given-names><suffix>Jr</suffix></name><name><surname>Lamendola</surname><given-names>C</given-names></name><name><surname>McLaughlin</surname><given-names>T</given-names></name><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group><article-title>Relationship between obesity, insulin resistance, and coronary heart disease risk</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><issue>5</issue><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(02)02051-X</pub-id><?supplied-pmid 12225719?><pub-id pub-id-type="pmid">12225719</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>TP</given-names></name><name><surname>Rawal</surname><given-names>K</given-names></name><name><surname>Bagchi</surname><given-names>AK</given-names></name><name><surname>Akolkar</surname><given-names>G</given-names></name><name><surname>Bernardes</surname><given-names>N</given-names></name><name><surname>Dias Dda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes</article-title><source>Heart Fail Rev</source><year>2016</year><volume>21</volume><issue>1</issue><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s10741-015-9515-6</pub-id><?supplied-pmid 26542377?><pub-id pub-id-type="pmid">26542377</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyengar</surname><given-names>NM</given-names></name><name><surname>Hudis</surname><given-names>CA</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name></person-group><article-title>Obesity and cancer: local and systemic mechanisms</article-title><source>Annu Rev Med</source><year>2015</year><volume>66</volume><fpage>297</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-050913-022228</pub-id><?supplied-pmid 25587653?><pub-id pub-id-type="pmid">25587653</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>D</given-names></name><name><surname>Rau</surname><given-names>M</given-names></name><name><surname>Hermanns</surname><given-names>HM</given-names></name><name><surname>Geier</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease</article-title><source>Cytokine Growth Factor Rev</source><year>2015</year><volume>26</volume><issue>6</issue><fpage>625</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.07.016</pub-id><?supplied-pmid 26250749?><pub-id pub-id-type="pmid">26250749</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nies</surname><given-names>VJ</given-names></name><name><surname>Sancar</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>van Zutphen</surname><given-names>T</given-names></name><name><surname>Struik</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Fibroblast Growth Factor Signaling in Metabolic Regulation</article-title><source>Front Endocrinol</source><year>2015</year><volume>6</volume><fpage>193</fpage></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrera</surname><given-names>F</given-names></name><name><surname>Azocar</surname><given-names>L</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>Schalper</surname><given-names>KA</given-names></name><name><surname>Ocares</surname><given-names>M</given-names></name><name><surname>Liberona</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19</article-title><source>Ann Hepatol</source><year>2015</year><volume>14</volume><issue>5</issue><fpage>710</fpage><lpage>721</lpage><?supplied-pmid 26256900?><pub-id pub-id-type="pmid">26256900</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcik</surname><given-names>M</given-names></name><name><surname>Janus</surname><given-names>D</given-names></name><name><surname>Dolezal-Oltarzewska</surname><given-names>K</given-names></name><name><surname>Kalicka-Kasperczyk</surname><given-names>A</given-names></name><name><surname>Poplawska</surname><given-names>K</given-names></name><name><surname>Drozdz</surname><given-names>D</given-names></name><etal/></person-group><article-title>A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents</article-title><source>J Pediatr Endocrinol Metab</source><year>2012</year><volume>25</volume><issue>11-12</issue><fpage>1089</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1515/jpem-2012-0253</pub-id><?supplied-pmid 23329754?><pub-id pub-id-type="pmid">23329754</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eren</surname><given-names>F</given-names></name><name><surname>Kurt</surname><given-names>R</given-names></name><name><surname>Ermis</surname><given-names>F</given-names></name><name><surname>Atug</surname><given-names>O</given-names></name><name><surname>Imeryuz</surname><given-names>N</given-names></name><name><surname>Yilmaz</surname><given-names>Y</given-names></name></person-group><article-title>Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease</article-title><source>Clin Biochem</source><year>2012</year><volume>45</volume><issue>9</issue><fpage>655</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2012.03.019</pub-id><?supplied-pmid 22465275?><pub-id pub-id-type="pmid">22465275</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Shaffer EA, Small DM. Biliary lipid secretion in cholesterol gallstone disease. The effect of cholecystectomy and obesity. J Clin Invest. 59(5):1977, 828&#x02013;40. PubMed Pubmed Central PMCID: 372291. Epub 1977/05/01. eng</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roda</surname><given-names>E</given-names></name><name><surname>Aldini</surname><given-names>R</given-names></name><name><surname>Mazzella</surname><given-names>G</given-names></name><name><surname>Roda</surname><given-names>A</given-names></name><name><surname>Sama</surname><given-names>C</given-names></name><name><surname>Festi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enterohepatic circulation of bile acids after cholecystectomy</article-title><source>Gut</source><year>1978</year><volume>19</volume><issue>7</issue><fpage>640</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1136/gut.19.7.640</pub-id><?supplied-pmid 567165?><pub-id pub-id-type="pmid">567165</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malagelada</surname><given-names>JR</given-names></name><name><surname>Go</surname><given-names>VL</given-names></name><name><surname>Summerskill</surname><given-names>WH</given-names></name><name><surname>Gamble</surname><given-names>WS</given-names></name></person-group><article-title>Bile acid secretion and biliary bile acid composition altered by cholecystectomy</article-title><source>Am J Dig Dis</source><year>1973</year><volume>18</volume><issue>6</issue><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/BF01076595</pub-id><?supplied-pmid 4705093?><pub-id pub-id-type="pmid">4705093</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids &#x00026; nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350&#x02013;362.</mixed-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannou</surname><given-names>GN</given-names></name></person-group><article-title>Cholelithiasis, cholecystectomy, and liver disease</article-title><source>Am J Gastroenterol</source><year>2010</year><volume>105</volume><issue>6</issue><fpage>1364</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.737</pub-id><?supplied-pmid 20068558?><pub-id pub-id-type="pmid">20068558</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez-Sanchez</surname><given-names>N</given-names></name><name><surname>Bahena-Aponte</surname><given-names>J</given-names></name><name><surname>Chavez-Tapia</surname><given-names>NC</given-names></name><name><surname>Motola-Kuba</surname><given-names>D</given-names></name><name><surname>Sanchez-Lara</surname><given-names>K</given-names></name><name><surname>Ponciano-Radriguez</surname><given-names>G</given-names></name><etal/></person-group><article-title>Strong association between gallstones and cardiovascular disease</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><issue>4</issue><fpage>827</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.41214.x</pub-id><?supplied-pmid 15784027?><pub-id pub-id-type="pmid">15784027</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>ME</given-names></name><name><surname>Attie</surname><given-names>AD</given-names></name><name><surname>Biddinger</surname><given-names>SB</given-names></name></person-group><article-title>The regulation of ApoB metabolism by insulin</article-title><source>Trends Endocrinol Metab</source><year>2013</year><volume>24</volume><issue>8</issue><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2013.04.001</pub-id><?supplied-pmid 23721961?><pub-id pub-id-type="pmid">23721961</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshad</surname><given-names>F</given-names></name><name><surname>Laway</surname><given-names>BA</given-names></name><name><surname>Rather</surname><given-names>TA</given-names></name><name><surname>Kuchay</surname><given-names>MS</given-names></name><name><surname>Khan</surname><given-names>SH</given-names></name></person-group><article-title>Impaired gallbladder motility in adults with newly detected type 2 diabetes and lack of reversibility after achieving euglycemia</article-title><source>Can J Diabetes</source><year>2015</year><volume>39</volume><issue>2</issue><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.jcjd.2014.07.223</pub-id><?supplied-pmid 25444680?><pub-id pub-id-type="pmid">25444680</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakeeb</surname><given-names>A</given-names></name><name><surname>Comuzzie</surname><given-names>AG</given-names></name><name><surname>Al-Azzawi</surname><given-names>H</given-names></name><name><surname>Sonnenberg</surname><given-names>GE</given-names></name><name><surname>Kissebah</surname><given-names>AH</given-names></name><name><surname>Pitt</surname><given-names>HA</given-names></name></person-group><article-title>Insulin resistance causes human gallbladder dysmotility</article-title><source>J Gastrointest Surg</source><year>2006</year><volume>10</volume><issue>7</issue><fpage>940</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1016/j.gassur.2006.04.005</pub-id><?supplied-pmid 16843864?><pub-id pub-id-type="pmid">16843864</pub-id></element-citation></ref></ref-list></back></article>